Bukwang Pharmaceutical reported a sharp decline in first-quarter operating profit, as higher manufacturing costs stemming from expanded outsourcing weighed on earnings.

LG CNS has moved to scale up its digital healthcare business through a strategic partnership with CHA Biotech(085660), the holding company of the CHA Bio Group.

Samyang Biopharm, the pharmaceutical and biotechnology subsidiary of South Korea’s Samyang Group, was listed on the Kospi on the 24th, marking its official debut on the nation’s main bourse.

Samsung Biologics announced on the 2nd that it has signed its largest-ever contract manufacturing (CMO) agreement, valued at 1.4637 trillion won ($1.06 billion), with a U.S.-based pharmaceutical company.

GCGenome, a specialized company in clinical genome analysis, enhances the organ transplant rejection test (dd-cfDNA testing).

DEEP:NEURO, an AI-driven brain aneurysm detection solution provided by DEEPNOID, a Korean AI healthcare company, was started to be seen in clinics and hospitals as a non-reimbursement item.

Il Dong Pharmaceutical announced it would supply its cardiovascular active pharmaceutical ingredient (API), Benidipine hydrochloride, to Chinese Guangzhou Tosun Pharmaceutical.

SM LNS (CEO Lim Seung-mo) has unveiled a microcurrent electric toothbrush, which effectively alleviates inflammation of teeth and gums and removes plaque in hard-to-reach areas after years of research.

GC Biopharma announced on the 3rd that it had signed a supply contract with Blau Farmaceutica, a local partner in Brazil, on the 30th of last month for its immunoglobulin blood product, “IVIG-SN 5%.” Through this contract, GC Biopharma will supply $90.84 million(about 119.4 billion won) worth of supplies to Brazil.

Hanmi Pharm announced two findings from research on LAPSTriple agonist (LAPSTriple) that the company was developing as an innovative new drug for non-alcoholic steatohepatitis (NASH).